Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response
Yan Mei(Kunming University of Science and Technology), Guangshuai Jia(Max Planck Institute for Heart and Lung Research), Xiuying Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Yingzhao Wang(Sun Yat-sen University), Lingdan Chen(First Affiliated Hospital of Guangzhou Medical University), Xianwen Ren(Peking University), Dan Liu(Peking University), Ji Zhang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xi Chen(Wellcome Sanger Institute), Xinyu Wang(Washington University in St. Louis), Hongyu Li(The University of Texas MD Anderson Cancer Center), Zhigang Liang(State Key Laboratory of Respiratory Disease), Hui Yuan(Anhui Medical University), Qingling Zhang(Jilin University), Qiu Li(University of Macau), Xiumei Wang(State Key Laboratory of New Ceramics and Fine Processing), Yong-Yi Feng(Sun Yat-sen University), Hongmin Bai(General Hospital of Guangzhou Military Command), Yiyi Li(Nanfang Hospital), Junjie He(Xuzhou Medical College), Jun Chen(The University of Texas MD Anderson Cancer Center), Yi Wei(China University of Geosciences), Lixiang Wang(Sun Yat-sen University), Chunliu Huang(Fujian Medical University), Qibin Leng(Chinese Academy of Sciences), Jing Liao(Guangzhou Medical University)
Cited by 219